Atyr Pharma Inc. (471A)
XFRA 
Summary
471A Chart
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial
aTyr Pharma NASDAQ: ATYR said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C meeting.
aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting
aTyr Pharma (NASDAQ: ATYR) CEO Sanjay Shukla outlined the company's strategy to develop new therapies for inflammation and fibrosis based on tRNA synthetase biology during a presentation at the Leerink Partners Global Healthcare Conference. Shukla focused primarily on efzofitimod, the company's lead program, including results from a global Phase 3 study in pulmonary sarcoidosis and the
Atyr Pharma Inc. (471A) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Atyr Pharma Inc. ever had a stock split?
Atyr Pharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sanjay S. Shukla CEO | XFRA Exchange | 002120202 CUSIP |
| US Country | 58 Employees | - Last Dividend | 1 Jul 2019 Last Split | - IPO Date |
Overview
aTyr Pharma, Inc. is a pioneering biotherapeutics company primarily engaged in the exploration and development of novel medicines targeting unique immunological pathways. With its foundation laid in 2005 and strategically headquartered in San Diego, California, aTyr Pharma is focused on the United States market, spearheading innovative solutions to address unmet medical needs in the domain of immune modulation. The company’s efforts center around harnessing the profound complexities of immunology to pioneer breakthrough treatments, positioning it at the forefront of addressing challenging diseases with significant impacts on patients' quality of life.
Products and Services
- efzofitimod (ATYR1923)
aTyr Pharma’s flagship therapeutic candidate, efzofitimod, epitomizes the company’s innovative approach. It is a selective modulator of Neuropilin-2 (NRP2), embodying a new class of therapeutics. Currently, efzofitimod is undergoing a Phase III clinical trial for pulmonary sarcoidosis, a condition that involves the growth of tiny inflammatory cells in various parts of the body, primarily the lungs. Additionally, it is in a Phase 1b/2a clinical trial for the treatment of other interstitial lung diseases (ILDs), including chronic hypersensitivity pneumonitis and connective tissue disease-related ILD, highlighting its potential as a versatile treatment option for multiple lung conditions.
- ATYR0101
Focused on tackling fibrotic diseases, ATYR0101 is a fusion protein based on a domain of aspartyl-tRNA synthetase. This novel compound is currently in the preclinical development stage and represents aTyr Pharma’s commitment to expanding its portfolio into treatments for fibrosis-affected organs and tissues. ATYR0101 reflects the company's expertise in protein-based therapeutics and its ability to exploit the therapeutic potential of tRNA synthetase domains.
- ATYR0750
Targeting liver disorders, ATYR0750 is another testament to aTyr Pharma’s innovative edge. This developmental candidate, derived from a domain of alanyl-tRNA synthetase, is aimed at treating various liver conditions. Currently in the research and development phase, ATYR0750 emphasizes the company’s dedication to leveraging its foundational science in tRNA synthetase biology to explore treatment options for a broader spectrum of diseases.
In addition to its product development efforts, aTyr Pharma has established a strategic collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd., focusing on the development and commercialization of efzofitimod for interstitial lung diseases in Japan. This partnership not only extends the global reach of aTyr’s innovative treatments but also underscores the international potential and recognition of its therapeutic candidates.
